-
- Rachel Krassenstein
- 1Departments of Surgical Oncology and2
-
- Edward Sauter
- Department of Surgery, Ellis Fischel Cancer Center/University of Missouri, Columbia, Missouri
-
- Essel Dulaimi
- 1Departments of Surgical Oncology and2
-
- Cristina Battagli
- 1Departments of Surgical Oncology and2
-
- Hormoz Ehya
- Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, and3
-
- Andres Klein-Szanto
- Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, and3
-
- Paul Cairns
- 1Departments of Surgical Oncology and2
抄録
<jats:title>Abstract</jats:title> <jats:p>Purpose: New approaches to the early detection of breast cancer are urgently needed as there is more benefit to be realized from screening. Nipple aspiration is a noninvasive technique that yields fluid known to contain breast epithelial cells. Silencing of tumor suppressor genes such as p16INk4a, BRCA1, and hMLH1 have established hypermethylation as a common mechanism for tumor suppressor inactivation in human cancer and as a promising target for molecular detection.</jats:p> <jats:p>Experimental Design: Using sensitive methylation-specific PCR, we searched for aberrant promoter hypermethylation in a panel of six normally unmethylated genes: glutathione S-transferase π 1 (GSTP1); retinoic acid receptor-β2 (RARβ2); p16INk4a; p14ARF; RAS association domain family protein 1A (RASSF1A); and death-associated protein kinase (DAP-kinase) in 22 matched specimens of tumor, normal tissue, and nipple aspirate fluid collected from breast cancer patients.</jats:p> <jats:p>Results: Hypermethylation of one or more genes was found in all 22 tumor DNAs (100% diagnostic coverage) and identical gene hypermethylation detected in 18 of 22 (82%) matched aspirate fluid DNAs. In contrast, hypermethylation was absent in benign and normal breast tissue and nipple aspirate DNA from healthy women.</jats:p> <jats:p>Conclusions: Promoter hypermethylation of important cancer genes is common in breast cancer and could be detected in matched aspirate DNAs from patients with ductal carcinoma in situ or stage I cancer. Promoter hypermethylation represents a promising marker, and larger studies may lead to its useful application in breast cancer diagnosis and management.</jats:p>
収録刊行物
-
- Clinical Cancer Research
-
Clinical Cancer Research 10 (1), 28-32, 2004-01-01
American Association for Cancer Research (AACR)
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1360294646794659328
-
- NII論文ID
- 30018691677
-
- ISSN
- 15573265
- 10780432
-
- データソース種別
-
- Crossref
- CiNii Articles